Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A

International Journal of Molecular Sciences(2025)10.3390/ijms26031210Source: DataRank Database

p21 Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A is a research paper published in International Journal of Molecular Sciences (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 4.01)OA: goldTopics (66)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Madeline Sutko,Trygve O. Tollefsbol ORCID,Andrew C. Brane ORCID

Live enrichment

PubMed:39940977 PMC:PMC11818515 OpenAlex:https://openalex.org/W4406986265

National Institutes of Health

Grant: T32CA047888

National Institutes of Health

Grant: NCI R01 CA178441

NCI NIH HHS

Grant: R01 CA178441

NCI NIH HHS

Grant: T32 CA47888

National Institutes of Health

Grant: 5T32CA047888-35

Cancer Prevention and Control Training Program

National Institutes of Health

Grant: 2R01CA178441-06A1

Combinatorial epigenetic-based prevention of breast cancer

FWCI

4.01

Citation Percentile

0.9%

Citation Trend

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/26/3/1210/pdf?version=1738235408

publisherhttps://www.mdpi.com/1422-0067/26/3/1210/pdf?version=1738235408

publisherhttps://www.mdpi.com/1422-0067/26/3/1210/pdf

journalhttps://doi.org/10.3390/ijms26031210

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39940977

Fields of Study

Phytochemicals and Medicinal PlantsCRISPR and Genetic EngineeringPARP inhibition in cancer therapy03 medical and health sciences0302 clinical medicineHumansWithanolidesDNA MethylationCyclin-Dependent Kinase Inhibitor p21Promoter Regions, GeneticBreast NeoplasmsMCF-7 CellsCell Line, TumorGene Expression Regulation, NeoplasticTumor Suppressor Protein p53FemaleCell SurvivalEpigenesis, GeneticAntineoplastic Agents

MeSH Terms

Antineoplastic AgentsBreast NeoplasmsCell SurvivalFemaleHumansPromoter Regions, GeneticGene Expression Regulation, NeoplasticTumor Suppressor Protein p53DNA MethylationEpigenesis, GeneticCell Line, TumorCyclin-Dependent Kinase Inhibitor p21WithanolidesMCF-7 Cells

Keywords

DNA methylationEpigeneticsWithaferin AMethylationPromoterBiologyCancer researchViability assayGeneticsGeneCell cultureGene expressionMedicineWithania somniferaPathologyBreast cancerPreventionPhytochemicalsCrispr-dcas9Cyclin-Dependent Kinase Inhibitor p21Cell SurvivalBreast NeoplasmsAntineoplastic AgentsArticleEpigenesis, GeneticGene Expression Regulation, NeoplasticCell Line, TumorMCF-7 CellsHumansFemaleTumor Suppressor Protein p53Promoter Regions, GeneticWithanolides

Sustainable Development Goals

SDG 0: Good health and well-being